

VPA22664/031/001

**Calciject 40 Solution for Injection**

<b>Variation</b>	<b>Summary</b>	<b>Date</b>
Vet - B44 a)	VNRA - Vet - B44 a) - - Vet - B44 a) - Submission of a Ph. Eur. CEP for:— active substance;— starting material, reagent or intermediate used in the manufacturing process of the active substance;— excipient - Updated certificate	04/03/26
Vet - B44 a)	VNRA - Vet - B44 a) - - Vet - B44 a) - Submission of a Ph. Eur. CEP for:— active substance;— starting material, reagent or intermediate used in the manufacturing process of the active substance;— excipient - Updated certificate	18/11/25
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	18/11/24
Vet - B3 f)	VNRA - Vet - B3 f) - f) Deletion of one of the authorised bulk or final containers (including packaging of an active substance) or immediate packaging of the finished product that does not lead to the complete deletion of a strength or pharmaceutical form - B3 f) Changes to the quality part of the dossier: Deletion of one of the authorised bulk or final containers (including packaging of an active substance) or immediate packaging of the finished product that does not lead to the complete deletion of a strength or pharmaceutical form	27/03/24
Vet - B21	VNRA - Vet - B21 - Replacement or addition of a secondary packaging site of a finished product - B21 Changes to the quality part of the dossier: Replacement or addition of a secondary packaging site of a finished product	27/03/24
Vet - B39	VNRA - Vet - B39 - Change in any part of the primary packaging material not in contact with the finished product formulation - B39 Changes to the quality part of the dossier: Change in any part of the primary packaging material not in contact with the finished product formulation (such as change of colour due to different plastic used for flip-off caps, colour code rings on ampoules or change of needle shield)	27/03/24
Vet - B43	VNRA - Vet - B43 - Editorial changes to part 2 of the dossier if	27/03/24

	inclusion in an upcoming procedure concerning part 2 is not possible - B43 Changes to the quality part of the dossier: Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible	
Vet - F.II.b.3 a)	VRA-R - Vet - F.II.b.3 a) - a) Minor change in the manufacturing process - F.II.b.3 a) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Minor change in the manufacturing process	27/03/24
Vet - F.II.b.4 z)	VRA-R - Vet - F.II.b.4 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.4 z) Quality Changes - Finished Product -Manufacture - Change in the batch size (including batch size ranges) of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	27/03/24
Vet - F.II.b.1 d)	VRA-R - Vet - F.II.b.1 d) - d) Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile veterinary medicinal products (including those that are aseptically manufactured) excluding biological/ immunological veterinary medicinal products - F.II.b.1 d) Quality Changes - Finished Product -Manufacture - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile veterinary medicinal products (including those that are aseptically manufactured) excluding biological/ immunological veterinary medicinal products	27/03/24
Vet - F.II.e.4 b)	VRA-R - Vet - F.II.e.4 b) - b) Sterile medicinal products - F.II.e.4 b) Quality Changes - Container closure system - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products	27/03/24
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	20/07/23